Japanese Encephalitis Pipeline Review Report, H2 2017 Edition - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Japanese Encephalitis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Japanese Encephalitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Japanese Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Japanese Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

1. Introduction
2. Japanese Encephalitis - Overview
3. Japanese Encephalitis - Therapeutics Development
4. Pipeline Overview
5. Pipeline by Companies
6. Pipeline by Universities/Institutes
7. Products under Development by Companies
8. Products under Development by Universities/Institutes
9. Japanese Encephalitis - Therapeutics Assessment
10. Assessment by Target
11. Assessment by Mechanism of Action
12. Assessment by Route of Administration
13. Assessment by Molecule Type
14. Japanese Encephalitis - Companies Involved in Therapeutics Development
    

• Adimmune Corp
• Cadila Healthcare Ltd
• Ennaid Therapeutics LLC
• Fab'entech SA
• Indian Immunologicals Ltd
• Kineta Inc
• Livzon Pharmaceutical Group Inc
• Panacea Biotec Ltd
• Theravectys SA

For more information about this report visit https://www.researchandmarkets.com/research/38k2pg/japanese?w=4